Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Depo-provera Ci Generic Name & Formulations
Legal Class
Rx
General Description
Medroxyprogesterone acetate 150mg/mL; IM inj.
Pharmacological Class
Progestin.
See Also
How Supplied
Vials—1, 25; Prefilled syringe (1mL)—1 (w. needles); SubQ (prefilled syringe)—1 (w. needle)
Manufacturer
Depo-provera Ci Indications
Indications
Injectable contraception.
Limitations of Use
Not recommended as a long-term (eg, >2yrs) birth control method unless other options are considered inadequate.
Depo-provera Ci Dosage and Administration
Adult
Give by deep IM inj in the gluteal or deltoid muscle; rotate inj sites. 150mg every 3 months (13 weeks). Give 1st dose within 5 days of onset of normal menses (see full labeling for postpartum).
Children
Pre-menarche: not applicable.
Depo-provera Ci Contraindications
Contraindications
Active thrombophlebitis. Thromboembolic disorders. Cerebrovascular disease. Breast carcinoma. Significant liver disease. Undiagnosed vaginal bleeding. Pregnancy.
Depo-provera Ci Boxed Warnings
Boxed Warning
Loss of bone mineral density.
Depo-provera Ci Warnings/Precautions
Warnings/Precautions
May lose significant bone mineral density (BMD). Evaluate BMD with long-term use or in adolescents. Risk for osteoporosis (eg, metabolic bone disease, anorexia, family history). Previous or family history of breast cancer (monitor closely). Ectopic pregnancy. History of depression; monitor for mood changes. Diabetes. Monitor conditions aggravated by fluid retention. Do pretreatment physical exam. Discontinue if jaundice or elevated transaminases, visual disturbances, migraine, or thrombotic disorders occur. Nursing mothers.
Depo-provera Ci Pharmacokinetics
See Literature
Depo-provera Ci Interactions
Interactions
May be antagonized by moderate or strong CYP3A4 inducers (eg, bosentan, efavirenz, etravirine, modafinil, rifampin, carbamazepine, phenytoin, phenobarbital, mitotane, St. John's wort, others); avoid. May reduce bone mass with anticonvulsants, corticosteroids; avoid alcohol, tobacco. May be affected by protease inhibitors, NNRTIs. May affect results of lab tests (eg, coagulation factors, lipids, glucose tolerance, and binding proteins); see full labeling.
Depo-provera Ci Adverse Reactions
Adverse Reactions
Dysfunctional uterine bleeding, headache, increased weight, amenorrhea, inj site reactions, vaginitis, abdominal pain, UTIs, acne; decreased BMD, anaphylaxis.
Depo-provera Ci Clinical Trials
See Literature
Depo-provera Ci Note
Not Applicable
Depo-provera Ci Patient Counseling
See Literature
